MDM2 and hepatocellular carcinoma: As shown in Table 1, the prevalence of autoantibody against MDM2 was 19.3% (47/244) in HCC, which was significantly higher than that in LC (P = 0.000), CH (P = 0.002), and NHS (P = 0.000).